BR0008645A - Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição - Google Patents
Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composiçãoInfo
- Publication number
- BR0008645A BR0008645A BR0008645-2A BR0008645A BR0008645A BR 0008645 A BR0008645 A BR 0008645A BR 0008645 A BR0008645 A BR 0008645A BR 0008645 A BR0008645 A BR 0008645A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- immune response
- cells
- methods
- tissue
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 9
- 210000004027 cell Anatomy 0.000 title abstract 8
- 230000028993 immune response Effects 0.000 title abstract 8
- 230000002163 immunogen Effects 0.000 title abstract 5
- 210000000056 organ Anatomy 0.000 title abstract 5
- 239000013612 plasmid Substances 0.000 title abstract 4
- 210000001519 tissue Anatomy 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 4
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 4
- 239000003053 toxin Substances 0.000 abstract 3
- 231100000765 toxin Toxicity 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- -1 AND Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Dentistry (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"MéTODOS DE INDUZIR UMA RESPOSTA IMUNOLóGICA CONTRA UM IMUNóGENO EM UM INDIVìDUO, DE REDUZIR REJEIçãO DE CéLULAS, TECIDO OU óRGãO DOADORES NãO-ASSEMELHADOS EM UM INDIVìDUO E UMA RESPOSTA IMUNOLóGICA DOMINANTE EM UM INDIVìDUO E DE EXPANDIR UMA SUBPOPULAçãO DE CéLULAS T ASSOCIADAS COM UMA RESPOSTA IMUNOLóGICA ESPECìFICA, PLASMìDEO, E, COMPOSIçãO". Divulga-se métodos de indução de uma resposta imunológica contra um imunógeno em um indivíduo. Os métodos compreendem administrar ao indivíduo, uma ou mais moléculas de ácido nucleico que compreendem uma seq³ência de nucleotídeos que codifica um imunógeno e uma seq³ência de nucleotídeos que codifica um antígeno de complexo de histocompatibilidade maior. As seq³ências de nucleotídeos que codificam o imunógeno e o antígeno de complexo de histocompatibilidade maior são expressas quando absorvidas por células do indivíduo, e uma resposta imunológica contra o imunógeno é induzida no indivíduo. Divulga-se métodos para reduzir rejeição de células, tecido ou órgão doadores não-assemelhados em um indivíduo que está sendo submetido a transplante de células, tecido ou órgão. Os métodos compreendem administrar ao indivíduo, uma ou mais moléculas de ácido nueleico que compreendem uma seq³ência de nucleotídeos que codifica um sinal de morte ou toxina e uma seq³ência de nucleotídeos que codifica um antígeno de complexo de histocompatibilidade maior que é assemelhado às células, tecido ou órgão doadores. As seq³ências de nucleotídeos que codificam o antígeno de complexo de histocompatibilidade maior e sinal de morte ou toxina são expressas quando absorvidas por células do indivíduo. A morte de células T através de interação com o sinal de morte ou toxina resulta numa redução de rejeição de células, tecido ou órgão doadores não-assemelhados. Descreve-se também métodos para reduzir uma resposta imunológica dominante em um indivíduo métodos para expandir uma subpopulação de células T associada com uma resposta imunológica específica. Descreve-se plasmídeos e composições compreendendo plasmídeos úteis para a prática do método.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12276999P | 1999-03-03 | 1999-03-03 | |
| PCT/US2000/005767 WO2000051432A1 (en) | 1999-03-03 | 2000-03-03 | Vaccines and gene therapy compositions and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0008645A true BR0008645A (pt) | 2002-01-22 |
Family
ID=22404659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0008645-2A BR0008645A (pt) | 1999-03-03 | 2000-03-03 | Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7943587B2 (pt) |
| EP (1) | EP1168918A4 (pt) |
| JP (1) | JP2002538090A (pt) |
| KR (2) | KR20070053815A (pt) |
| CN (1) | CN1348332A (pt) |
| AU (2) | AU774265B2 (pt) |
| BR (1) | BR0008645A (pt) |
| CA (1) | CA2362873A1 (pt) |
| IL (2) | IL144845A0 (pt) |
| MX (1) | MXPA01008883A (pt) |
| WO (1) | WO2000051432A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070053815A (ko) * | 1999-03-03 | 2007-05-25 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 백신 및 유전자요법 조성물 및 이들의 제조 및 사용방법 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US20050084967A1 (en) * | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| EP1559783A1 (de) * | 2004-01-29 | 2005-08-03 | Qiagen GmbH | Verfahren zur chromatographischen Trennung eines Nukleinsäuregemisches |
| TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| US20090191218A1 (en) | 2005-05-11 | 2009-07-30 | Fengchun Li | DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
| AU2006247857B2 (en) * | 2005-05-11 | 2009-10-22 | Loma Linda University | Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders |
| JP2009511572A (ja) * | 2005-10-16 | 2009-03-19 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 炎症性皮膚疾患、障害または症状のための医薬組成物および診断方法 |
| ES2385204T3 (es) * | 2006-09-28 | 2012-07-19 | Loma Linda University | Transfección mediada por células apoptóticas de células de mamífero con ARN de interferencia |
| EP2249645B1 (en) * | 2008-03-12 | 2017-09-20 | Loma Linda University | Dna vaccines and methods for the prevention of transplantation rejection |
| EP2265715B1 (en) | 2008-04-04 | 2016-12-28 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same |
| US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
| ES2806605T3 (es) | 2011-09-23 | 2021-02-18 | Univ Loma Linda | Cepas bacterianas que expresan genes de metilasa y sus usos |
| EP2968607B1 (en) * | 2013-03-15 | 2019-07-24 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| JP3004049B2 (ja) | 1989-03-31 | 2000-01-31 | ワシントン ユニバーシティー | 病原性のないｐｈｏＰ型微生物を含有するワクチン |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| DE69016956T2 (de) | 1989-12-04 | 1995-07-20 | Akzo Nobel Nv | Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor. |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5738852A (en) * | 1993-04-20 | 1998-04-14 | Solis Therapeutics, Inc. | Methods of enhancing antigen-specific T cell responses |
| US5614503A (en) | 1993-11-12 | 1997-03-25 | Aronex Pharmaceuticals, Inc. | Amphipathic nucleic acid transporter |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| EP0870040A2 (en) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Gene delivery vehicle-targeting ligands |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| BR9712852A (pt) * | 1996-10-23 | 1999-11-16 | Univ Pennsylvania | Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado |
| US5726283A (en) | 1997-01-03 | 1998-03-10 | Far Eastern Textile, Ltd. | Conductive polyester sheet |
| KR20070053815A (ko) * | 1999-03-03 | 2007-05-25 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 백신 및 유전자요법 조성물 및 이들의 제조 및 사용방법 |
-
2000
- 2000-03-03 KR KR1020077009141A patent/KR20070053815A/ko active IP Right Grant
- 2000-03-03 EP EP00916099A patent/EP1168918A4/en not_active Withdrawn
- 2000-03-03 KR KR1020017011152A patent/KR20010103788A/ko not_active Application Discontinuation
- 2000-03-03 CA CA002362873A patent/CA2362873A1/en not_active Abandoned
- 2000-03-03 MX MXPA01008883A patent/MXPA01008883A/es unknown
- 2000-03-03 CN CN00804535A patent/CN1348332A/zh active Pending
- 2000-03-03 AU AU37258/00A patent/AU774265B2/en not_active Ceased
- 2000-03-03 WO PCT/US2000/005767 patent/WO2000051432A1/en not_active Application Discontinuation
- 2000-03-03 JP JP2000601912A patent/JP2002538090A/ja not_active Ceased
- 2000-03-03 BR BR0008645-2A patent/BR0008645A/pt not_active Application Discontinuation
- 2000-03-03 IL IL14484500A patent/IL144845A0/xx unknown
-
2001
- 2001-08-09 IL IL144845A patent/IL144845A/en not_active IP Right Cessation
-
2002
- 2002-05-06 US US10/139,423 patent/US7943587B2/en not_active Expired - Lifetime
-
2004
- 2004-09-24 AU AU2004214575A patent/AU2004214575B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010103788A (ko) | 2001-11-23 |
| EP1168918A4 (en) | 2002-08-21 |
| US20030176378A1 (en) | 2003-09-18 |
| AU2004214575B2 (en) | 2007-11-22 |
| AU2004214575A1 (en) | 2004-10-21 |
| MXPA01008883A (es) | 2003-07-21 |
| AU774265B2 (en) | 2004-06-24 |
| WO2000051432A1 (en) | 2000-09-08 |
| KR20070053815A (ko) | 2007-05-25 |
| CN1348332A (zh) | 2002-05-08 |
| AU3725800A (en) | 2000-09-21 |
| IL144845A0 (en) | 2002-06-30 |
| CA2362873A1 (en) | 2000-09-08 |
| EP1168918A1 (en) | 2002-01-09 |
| IL144845A (en) | 2012-06-28 |
| JP2002538090A (ja) | 2002-11-12 |
| US7943587B2 (en) | 2011-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0008645A (pt) | Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição | |
| Reubi et al. | Dopamine selectively increases 3H-GABA release from slices of rat substantia nigra in vitro | |
| Marcus et al. | An Alternate Complement Pathway: C-3 Cleaving Activity, Not Due to [unk], on Endotoxic Lipopolysaccharide after Treatment with Guinea Pig Serum; Relation to Properdin | |
| Flower | Prostaglandins, bioassay and inflammation | |
| Zheng et al. | E ndomicrobium proavitum, the first isolate of E ndomicrobia class. nov.(phylum E lusimicrobia)–an ultramicrobacterium with an unusual cell cycle that fixes nitrogen with a G roup IV nitrogenase | |
| Dudai et al. | Purification by affinity chromatography of acetylcholinesterase from electric organ tissue of electric eel subsequent to tryptic treatment | |
| Fitzpatrick et al. | A calcium pump in vascular smooth muscle | |
| DK1115840T3 (da) | Afstamningsspecifikke celler og progenitorceller | |
| Zhai et al. | Profile of the skin microbiota in a healthy Chinese population | |
| Hidaka et al. | Effect of novel specific myosin light chain kinase inhibitors on Ca2+-activated Mg2+-ATPase of chicken gizzard actomyosin | |
| BR0012069A (pt) | Composições e métodos para a terapia e diagnóstico de câncer pulmonar | |
| Foster et al. | Subunits of the H+-ATPase of Escherichia coli. Overproduction of an eight-subunit F1F0-ATPase following induction of a lambda-transducing phage carrying the unc operon. | |
| BRPI1006135A2 (pt) | Bactérias do ácido láctico e seu uso em produtos microbianos para ração direta a suínos | |
| Sakamoto et al. | Collagenase and bone resorption: isolation of collagenase from culture medium containing serum after stimulation of bone resorption by addition of parathyroid hormone extract | |
| BR0016212A (pt) | Proteìna especìfica do cromossoma sexual e sequência de ácido nucleico isolada e purificada, método para identificar moléculas especìficas de cromossomas sexuais associadas com membranas celulares de esperma animal, anticorpo contra um epìtopo de uma molécula especìfica de cromossomas sexuais, métodos de triagem para uma molécula especifica de cromossomas sexuais, e para separar esperma determinante de macho e fêmea de sêmen nativo kit para executar um método, contraceptivo, proteìna especìfica do cromossoma sexual isolada e purificada, e , molécula | |
| McDaniel et al. | Anorexic effect of K+ channel blockade in mesenteric arterial smooth muscle and intestinal epithelial cells | |
| BR9815440A (pt) | Células intestinais parasitas viáveis isoladas | |
| Okamoto et al. | Intramitochondrial localization of kynurenine aminotransferase | |
| Ikehara et al. | Stimulation of the binding of aminoacyl-sRNA to ribosomes by tubercidin (7-deazaadenosine) and N6-dimethyladenosine containing trinucleoside diphosphate analogs | |
| Lichstein et al. | On the permeability of Lactobacillus arabinosus to biotin | |
| Oriol-Audit | Actin-polyamines interaction: Relationship between physicochemical properties and cytokinesis induction | |
| Welsh et al. | Heat-shock treatment of mouse pancreatic islets results in a partial loss of islet cells but no remaining functional impairment among the surviving β cells | |
| BR0318058A (pt) | Processo para a preparação fermentativa de l-aminoácidos usando cepas da famìlia enterobacteriaceae que contêm uma sequência orf yjgf atenuada | |
| Blue et al. | Detection of a DNA polymerase β stimulating protein in HeLa cell nuclear extracts | |
| BR0314986A (pt) | Sequência de polinucleotìdeo, vetor de expressão, composição farmacêutica, usos de uma sequência de polinucleotìdeo, de um vetor e de uma composição, e, método para tratar ou prevenir infecções pelo hpv ou qualquer sintomas ou doenças associados com elas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 48/00 (2010.01), C12N 15/85 (2010.01), C07H 2 |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII) DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |